"The ANSM also fined Lilly France €108,766 for a campaign promoting its anti-obesity drug Mounjaro, seeing the adverts as 'likely to constitute indirect promotion of medicines subject to mandatory medical prescription.'"
"The national medicines regulator said that the fines aimed to 'prevent any communication likely to promote the use of drug treatment as the principal response to obesity, to encourage the public to request this treatment from a healthcare professional or seek to obtain it themselves.'"
"Novo Nordisk France said it 'strongly contests' the ANSM's finding, adding it is 'exploring all possible appeal avenues against this decision.'"
"According to a French study published in 2024, around 18 percent of the French population - equivalent to some ten million people - are obese."
The ANSM imposed fines on Novo Nordisk and Eli Lilly for their advertising campaigns promoting anti-obesity drugs. Novo Nordisk was fined €1.78 million for Saxenda and Wegovy promotions, while Lilly faced a €108,766 fine for Mounjaro. French law prohibits public advertising of prescription medications. The ANSM aims to prevent misleading communications that could encourage inappropriate drug use for obesity treatment. Novo Nordisk contests the findings, while Lilly believes its campaign complied with health communication regulations. Approximately 18% of the French population is obese, highlighting the significance of these regulations.
Read at The Local France
Unable to calculate read time
Collection
[
|
...
]